Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib, an investigational oral WEE1 inhibitor designed to disrupt DNA damage response in cancer cells and drive them toward cell death. The company's lead therapeutic approach targets Cyclin E1-positive platinum-resistant ovarian cancer patients, a subset identified through a proprietary biomarker strategy, and is advancing azenosertib through multiple clinical trials with potential for accelerated regulatory approval. Zentalis relies on third-party contract manufacturing for production and generates revenue exclusively through eventual regulatory approval and commercialization of its azenosertib program, competing with chemotherapy and other emerging cancer therapies in a competitive landscape where no WEE1 inhibitors have yet received FDA approval.